2025-522217-27-00CompletedPhase 1
The effect of SYX-5219 on an immune response in the skin.
Source: EU CTIS (euclinicaltrials.eu) · Last updated 14 Nov 2025
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (actual)
- First submitted
- 15 Sept 2025
- Start date
- 19 Nov 2025
- Lead sponsor
- Sitryx Therapeutics Limited
- Diseases
- Atopic dermatitis (eczema)
- EU CT number
- 2025-522217-27-00
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 20
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Centre for Human Drug Research | Leiden | Netherlands | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.